Selected articles
Articles for label Spisarová Martina are displayed.. Show all articles
Axitinib treatment after rapid progression of metastatic renal cell carcinoma during sunitinib administration - case report
06/2019 MUDr. Martina Spisarová
Angiogenesis is a crucial part of process in which benign tumors become into more aggressive malignant form and also their subsequent growth and dissemination. The correlation between inhibition of VEGF receptor and its curative effect has been observed in tumors with high microvascular density for a long time. The inhibition of VEGF receptor has a huge therapeutic potential in clear cell renal carcinoma and suchlike tumors.
ENTIRE ARTICLE
Angiogenesis is a crucial part of process in which benign tumors become into more aggressive malignant form and also their subsequent growth and dissemination. The correlation between inhibition of VEGF receptor and its curative effect has been observed in tumors with high microvascular density for a long time. The inhibition of VEGF receptor has a huge therapeutic potential in clear cell renal carcinoma and suchlike tumors.
Introduction to immunotherapy
Supplementum 01/2019 Imunoterapie
MUDr. Martina Spisarová; prof. MUDr. Bohuslav Melichar, Ph.D.
Tumor diseases are one of the most common causes of death worldwide and affect all ages. Current advances in malignant therapy are both in the field of surgical treatment, which remains a key curative method of early stages of the disease, as well as in the field of radiotherapy, chemotherapy and, last but not least, targeted treatments that help us to overcome the limits of standard cancer therapies. Even primarily effective targeted therapy often encounters the development of secondary resistance after a certain period of time. The role of the immune system, or the tumor cells escaping from its surveillance, is unquestionable in the development of cancer. Influencing the individual steps of the immune response seemed to be a very promising method how to influence the course of cancer, and in the last few years, this assumption has been confirmed by an ever-expanding number of diagnoses where modern immunotherapy in patients prolongs survival. The key diagnosis has become a disease that, thanks to its chemoresistance and radioresistance, for decades prompted the discovery of other treatment options.
ENTIRE ARTICLE
MUDr. Martina Spisarová; prof. MUDr. Bohuslav Melichar, Ph.D.
Tumor diseases are one of the most common causes of death worldwide and affect all ages. Current advances in malignant therapy are both in the field of surgical treatment, which remains a key curative method of early stages of the disease, as well as in the field of radiotherapy, chemotherapy and, last but not least, targeted treatments that help us to overcome the limits of standard cancer therapies. Even primarily effective targeted therapy often encounters the development of secondary resistance after a certain period of time. The role of the immune system, or the tumor cells escaping from its surveillance, is unquestionable in the development of cancer. Influencing the individual steps of the immune response seemed to be a very promising method how to influence the course of cancer, and in the last few years, this assumption has been confirmed by an ever-expanding number of diagnoses where modern immunotherapy in patients prolongs survival. The key diagnosis has become a disease that, thanks to its chemoresistance and radioresistance, for decades prompted the discovery of other treatment options.
Combination of BRAF and MEK inhibitors in the treatment of advanced malignant melanoma harbouring BRAF V600 mutation
01/2019 MUDr. Radmila Lemstrová, Ph.D.; MUDr. Martina Spisarová
Immunotherapy and targeted therapy have radically changed prognosis of patients with advanced malignant melanoma. Nowadays up to 40 % of patients reach long term remission of disease. Around 50 % of malignant melanomas harbor BRAF V600 mutation. Combination of BRAF and MEK inhibitors in the treatment of BRAF V600 mutated melanomas has led to increased efficacy with acceptable toxicity of the treatment. Unfortunately, the secondary resistance develops to combination therapy too. New strategies to overcome the secondary resistance are subject of many clinical trials as well as appropriate sequence of treatment of BRAF V600 mutated melanoma. The results of ongoing clinical trials will hopefully lead to further optimizing of the treatment. This review summarizes the combination of vemurafenib and cobimetinib in the treatment of advanced BRAF V600 mutated malignant melanoma.
ENTIRE ARTICLE
Immunotherapy and targeted therapy have radically changed prognosis of patients with advanced malignant melanoma. Nowadays up to 40 % of patients reach long term remission of disease. Around 50 % of malignant melanomas harbor BRAF V600 mutation. Combination of BRAF and MEK inhibitors in the treatment of BRAF V600 mutated melanomas has led to increased efficacy with acceptable toxicity of the treatment. Unfortunately, the secondary resistance develops to combination therapy too. New strategies to overcome the secondary resistance are subject of many clinical trials as well as appropriate sequence of treatment of BRAF V600 mutated melanoma. The results of ongoing clinical trials will hopefully lead to further optimizing of the treatment. This review summarizes the combination of vemurafenib and cobimetinib in the treatment of advanced BRAF V600 mutated malignant melanoma.